BI Asset Management Fondsmaeglerselskab A S Purchases New Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 116,758 shares of the biopharmaceutical company's stock, valued at approximately $2,437,000. BI Asset Management Fondsmaeglerselskab A S owned about 0.10% of Catalyst Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Summit Investment Advisors Inc. grew its position in shares of Catalyst Pharmaceuticals by 5.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 580 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Catalyst Pharmaceuticals by 6.2% during the 4th quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock valued at $311,000 after purchasing an additional 875 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Catalyst Pharmaceuticals by 0.3% during the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock valued at $6,518,000 after purchasing an additional 952 shares in the last quarter. Handelsbanken Fonder AB boosted its position in shares of Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock valued at $740,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Xponance Inc. boosted its position in shares of Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company's stock valued at $392,000 after purchasing an additional 1,189 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Up 1.1 %

CPRX stock traded up $0.26 during midday trading on Friday, reaching $23.45. 612,029 shares of the company's stock traded hands, compared to its average volume of 1,108,879. The company has a market cap of $2.86 billion, a price-to-earnings ratio of 19.87, a P/E/G ratio of 3.31 and a beta of 0.79. The firm's fifty day moving average price is $22.58 and its 200-day moving average price is $22.22. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CPRX shares. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Bank of America restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.